Skip to main content
Log in

A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

At the time of castration resistance, it is recommended to realize hormonal manipulations before chemotherapy. We evaluated the impact of a switch from GnRH agonist to antagonist in patients with castration-resistant prostate cancer on PSA and testosterone levels at 3 months.

Methods

Retrospectively, 17 patients from 5 different centers undergoing androgen deprivation therapy and presenting rising PSA confirmed on 3 blood samples 2 weeks apart and despite a castrate testosterone level (<0.5 ng/ml) were reviewed. Antiandrogen withdrawal syndrome had been tested before the switch. Degarelix was administered as followed: 240 mg for the first injection and then 80 mg every month, subcutaneously. We evaluated the PSA and testosterone level variation 3 months after the switch. Patients who experienced a variation in PSA of less than 10% compared to the baseline or who had a more than 10% PSA decrease were defined as responders.

Results

Mean PSA level at the switch was 34.3 ± 50.3 ng/ml, with a mean testosterone level of 0.21 ± 0.13 ng/ml. Three months after the switch, mean PSA level was 59.9 ± 81.6 ng/ml (P = 0.061), with a mean testosterone level of 0.19 ± 0.08 ng/ml (P = 0.086). At 3 months, 4 patients (23%) responded to therapy. Thirteen patients (77%) experienced a rise in PSA of more than 10% compared to baseline; 41% of patients decreased their testosterone level. The limitations of this study are its retrospective nature and the limited number of patients.

Conclusion

Switch from an agonist to an antagonist of GnRH has a limited impact on PSA at 3 months in castration-resistant prostate cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS (2006) Secondary hormonal therapy for advanced prostate cancer. J Urol 175(1):27–34. doi:10.1016/S0022-5347(05)00034-0

    Article  PubMed  CAS  Google Scholar 

  2. Van Poppel H (2010) Evaluation of degarelix in the management of prostate cancer. Cancer Manag Res 2:39–52

    PubMed  Google Scholar 

  3. de la Rosette J, Davis R 3rd, Frankel D, Kold Olesen T (2011) Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer. Int J Clin Pract 65(5):559–566. doi:10.1111/j.1742-1241.2011.02637.x

    Article  PubMed  Google Scholar 

  4. Raddin RS, Walko CM, Whang YE (2011) Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer. Anticancer Drugs 22(3):299–302

    Article  PubMed  CAS  Google Scholar 

  5. Lawrentschuk N, Fernandes K, Bell D, Barkin J, Fleshner N (2011) Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol 185(3):848–854. doi:10.1016/j.juro.2010.10.055

    Article  PubMed  CAS  Google Scholar 

  6. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE (2011) A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 186(3):889–897. doi:10.1016/j.juro.2011.04.083

    Article  PubMed  CAS  Google Scholar 

  7. Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M, Ding C, Wang W, Horak ID, Kremer AB (1999) Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91(3):244–251

    Article  PubMed  CAS  Google Scholar 

  8. Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT, Ghinea N (2010) Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363(17):1621–1630. doi:10.1056/NEJMoa1001283

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Alexandre de la Taille and Morgan Rouprêt have been occasional members of advisory board for FERRING.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alexandre de la Taille.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masson-Lecomte, A., Guy, L., Pedron, P. et al. A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA. World J Urol 31, 339–343 (2013). https://doi.org/10.1007/s00345-012-0841-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-012-0841-1

Keywords

Navigation